Abiologics is pioneering a new class of therapeutics known as Synteins™, which are designed to transcend the limitations of traditional biologics. By leveraging advanced generative artificial intelligence and high-throughput chemical protein synthesis, Abiologics creates these supranatural and programmable medicines. Synteins™ are constructed from a diverse array of artificial building blocks, including D-amino acids, which allow for the development of biologics with novel structures and enhanced properties. This innovative approach enables the design of therapeutics that can evade the immune system and resist degradation, thereby improving their efficacy and durability in treating a wide range of diseases.

The Abiologics platform integrates digital design and automated synthesis to produce these advanced biologics. By applying the predictable folding rules of natural proteins, the platform generates blueprints for Synteins™ that are specifically tailored for therapeutic targets. This capability allows for the creation of medicines that are not only compatible with human biology but also possess unique advantages, such as the potential for oral delivery and longer-lasting effects compared to conventional biologics. Ultimately, Abiologics aims to revolutionize treatment paradigms by offering innovative solutions that enhance patient outcomes across various therapeutic areas.

United States

Abiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins with powerful, desirable pharmacological properties, redefining what therapeutics can achieve for patients across a range of disease areas. Abiologics was founded by Flagship Pioneering in 2021.

Abiologics

Company Details